Identity
Melatonin is a hormone involved in sleep timing, not a peptide.
Source-specific finding, not full clinical sign-off.
Peptide library
Melatonin
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The controlled trial concerned confirmed delayed sleep-wake phase disorder with behavioral scheduling. Its results cannot establish a universal sleep aid, an optimal time for every person or indefinite use.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
116 participants with confirmed delayed sleep-wake phase disorder.
What the sources found
With behavioral scheduling, fast-release melatonin advanced sleep onset versus placebo over four weeks. This does not establish benefit for every sleep problem.
Regulatory scope
Current authorization must be checked for the exact product, indication and jurisdiction.
What remains unknown
Limited selected-source check, not an exhaustive review. Full methods, complete safety, exact formulation/route pharmacokinetics, stability and current jurisdictional authorization remain outstanding.
How it works
Melatonin is a hormone involved in sleep timing, not a peptide.
Read the source-specific findings; biological activity is not equivalent to a clinical treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- Light-headedness and daytime sleepiness were reported; long-term safety was not assessed.
Source-specific finding, not full clinical sign-off.
Contraindications
- Full clinical contraindication and interaction assessment remains outstanding.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
With behavioral scheduling, fast-release melatonin advanced sleep onset versus placebo over four weeks. This does not establish benefit for every sleep problem.
Source-specific finding, not full clinical sign-off.
Adverseeffects
Light-headedness and daytime sleepiness were reported; long-term safety was not assessed.
Source-specific finding, not full clinical sign-off.
References
Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial. 2018.
PMID: 29912983
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.